Catarina D. Campbell

Author

Also Known As

C Campbell, Campbell, Catarina, Campbell, Catarina D, Catarina Campbell, Catarina D Campbell, Catarina D. Campbell, Catarina D. Campbell

Publications

3.4K

Citations

H-Index

Concepts

All Affiliations

Harvard University Novartis (United States)Massachusetts General Hospital University of Washington Broad Institute

About

Catarina D. Campbell is an author at Harvard University specializing in medicine, genetics, and genetic epidemiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	731
2	Public Health	3	3	322
3	Education	1	1	448
4	Health Sciences	1	1	36
5	Allergy	1	1	37

Catarina D. Campbell

Publications

3.1K

Citations

H-Index

Page 1

	Year	Citations
Demonstrating stratification in a European American population Catarina D. Campbell, Elizabeth L. Ogburn, Kathryn L. Lunetta, Nature Genetics EthnicityEuropean American PopulationDemographic ChangePopulation ScienceEducation	2005	448
Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples Laura E. MacConaill, Catarina D. Campbell, Sarah M. Kehoe, PLoS ONE	2009	432
<i>TET2</i>-Driven Clonal Hematopoiesis and Response to Canakinumab E. C. Svensson, Aviv Madar, Catarina D. Campbell, JAMA Cardiology	2022	333
Association of <i>MTOR</i> Mutations With Developmental Brain Disorders, Including Megalencephaly, Focal Cortical Dysplasia, and Pigmentary Mosaicism Ghayda Mirzaa, Catarina D. Campbell, Nadia Solovieff, JAMA Neurology	2016	272
Estimating the human mutation rate using autozygosity in a founder population Catarina D. Campbell, Jessica X. Chong, Maika Malig, Nature Genetics Genetic AnalysisHuman Mutation RateGenetic TestingMolecular EcologyGenetic Disorder	2012	233
Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial Jun Tian, Jonathan Chen, Sherry Chao, Nature Medicine	2023	164
PureCN: copy number calling and SNV classification using targeted short read sequencing Markus Riester, Angad Singh, A. Rose Brannon, Source Code for Biology and Medicine	2016	159
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial Reinhard Dummer, Jan C. Brase, James E. Garrett, The Lancet Oncology Trametinib Versus PlaceboMedicineMelanomaImmunologyPathology	2020	151
Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors Through Longitudinal Analysis of Circulating Tumor DNA Ibiayi Dagogo‐Jack, A. Rose Brannon, Lorin A. Ferris, JCO Precision Oncology	2018	129
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i Reinhard Dummer, Célèste Lebbé, Victoria Atkinson, Nature Medicine OncologyMedicineMelanomaImmunologyImmune Checkpoint Inhibitor	2020	121

Page 1